GlassScriptPhysician profile
Nick Huang
NPI 1508220120
$1,293.07
in general payments reported to CMS, 2019-2025
29 companies · $625 in 2025
The $625 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.73 · 2021: $20.00 · 2022: $49.87 · 2023: $232 · 2024: $353 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995 · Honoraria: $200 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.51 |
| Honoraria | $200.00 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $244.63 | 2023-2025 | |
| Daiichi Sankyo INC. | $215.33 | 2023-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $200.21 | 2025 | Imfinzi, Enhertu |
| Pfizer INC. | $67.11 | 2024-2025 | |
| Incyte Corporation | $66.55 | 2022-2024 | Pemazyre, Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $56.99 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| E.R. Squibb & Sons, L.L.C. | $32.89 | 2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $31.80 | 2021-2022 | |
| Kite Pharma, INC. | $23.24 | 2024 | Yescarta |
| Abbvie INC. | $22.79 | 2025 | |
| Stemline Therapeutics INC. | $22.63 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $21.91 | 2025 | Besremi |
| Octapharma USA, INC. | $21.46 | 2024 | Octagam Immune Globulin (Human) |
| Gilead Sciences, INC. | $19.11 | 2024 | |
| Genentech USA, INC. | $19.06 | 2025 | Itovebi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $18.16 | 2024 | Krazati |
| Taiho Oncology, INC. | $17.78 | 2024 | |
| Karyopharm Therapeutics INC. | $17.71 | 2024 | Xpovio |
| Janssen Biotech, INC. | $17.44 | 2025 | Rybrevant |
| Beone Medicines USA, INC. | $16.98 | 2025 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $16.79 | 2025 | |
| Astellas Pharma US INC | $16.48 | 2025 | Padcev |
| Puma Biotechnology, INC. | $16.47 | 2023 | |
| Agios Pharmaceuticals, INC. | $16.03 | 2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $15.96 | 2024 | Libtayo |
| Tersera Therapeutics LLC | $15.90 | 2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $15.31 | 2024 | |
| Emd Serono, INC. | $13.62 | 2024 | |
| Boston Scientific Corporation | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.